{
    "clinical_study": {
        "@rank": "153188", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "co-administration"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "MenB"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Active Comparator", 
                "description": "MenACWY"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to evaluate the immunogenicity, the safety and the tolerability\n      of rMenB+OMV NZ and MenACWY vaccines in healthy infants, when concomitantly administered at\n      3, 5, 7 and 13 months of age, compared to either alone."
        }, 
        "brief_title": "Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningococcal Disease", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy 3-month old infants whose parents/legal guardians have given written informed\n             consent\n\n          -  Available for all the visits scheduled in the study.\n\n          -  In good health as determined by medical history, physical examination and clinical\n             judgment of the investigator.\n\n        Exclusion Criteria:\n\n          -  History of any previous immunization with a meningococcal vaccine or vaccine\n             containing meningococcal antigen(s) (licensed or investigational) at the time of\n             enrollment.\n\n          -  Previous known or suspected disease caused by N. meningitidis.\n\n          -  Household contact with and/or intimate exposure to an individual with laboratory\n             confirmed N. meningitidis infection or colonization.\n\n          -  Family members or household members of site research staff.\n\n          -  History of severe allergic reaction after previous vaccinations, or hypersensitivity\n             to any component of the vaccine.\n\n          -  Known or suspected autoimmune disease or impairment/alteration of the immune system\n\n          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral\n             immunoglobulin preparation since birth.\n\n          -  History of any progressive or severe neurologic disorder, or seizure disorder or\n             Guillan Barr\u00e9 syndrome (exception: one self-limited febrile seizure is acceptable).\n\n          -  Receipt of any investigational or non-registered product (drug or vaccine) since\n             birth (3 month prior) or are expected to receive during the study period.\n\n          -  History or any illness/condition that, in the opinion of the investigator, might\n             interfere with the results of the study or pose additional risk to the subjects due\n             to participation in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "119 Days", 
            "minimum_age": "85 Days"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106390", 
            "org_study_id": "V72_56"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "rMenB+OMV  given concomitantly with MenACWY at 3,5,7 and 13  months of age", 
                "intervention_name": "rMenB+OMV  and MenACWY", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "rMenB+OMV  given at 3,5,7 and 13 months of age", 
                "intervention_name": "rMenB+OMV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group C", 
                "description": "MenACWY given at 3,5,7 and 13 months of age", 
                "intervention_name": "MenACWY", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Meningitis, vaccination, infant", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "vax_ar@yahoo.com", 
                    "last_name": "Alejandro Capdevila", 
                    "phone": "(5411) 4806-1350"
                }, 
                "facility": {
                    "address": {
                        "city": "Ciudad Autonoma de Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "(C1425DEM)"
                    }, 
                    "name": "Site 401"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "angelagentile@fibertel.com.ar; agentile@intramed.net", 
                    "last_name": "Angela Leonor Spagnuolo de Gentile", 
                    "phone": "54 11 4964-9019"
                }, 
                "facility": {
                    "address": {
                        "city": "Ciudad Autonoma de Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "(C1425EFD)"
                    }, 
                    "name": "Site 402, Dr Norberto Giglio / Veronica Umido"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "r.ruttimann@speedy.com.ar", 
                    "last_name": "Ricardo Ruttiman", 
                    "phone": "54 9 1115 6120-4819"
                }, 
                "facility": {
                    "address": {
                        "city": "Ciudad Autonoma de Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1426EOT"
                    }, 
                    "name": "Site 404, Fernando Aguirre / TBC"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hjabate@gmail.com", 
                    "last_name": "H\u00e9ctor Jos\u00e9 Abate", 
                    "phone": "0261-4454775"
                }, 
                "facility": {
                    "address": {
                        "city": "Mendoza", 
                        "country": "Argentina", 
                        "zip": "(5519)"
                    }, 
                    "name": "Site 404, Noelia Barraza"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Argentina"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Mexico: Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To demonstrate the immunological non-inferiority of rMenB+OMV NZ and MenACWY when concomitantly administered compared to either alone, at one month following the fourth vaccination.", 
            "measure": "Between-group ratios of hSBA Geometric Mean Titers (GMTs)  for all serogroups B (all indicator strains), A, C, W-135 and Y.", 
            "safety_issue": "No", 
            "time_frame": "30 days after 4th vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106390"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the immune response of rMenB+OMV NZ and MenACWY when concomitantly administered compared to either alone at\none month after the fourth vaccination\none month  after the third vaccination\nsix months after the third vaccination\nTo asses the safety and tolerability of rMenB+OMV NZ and MenACWY when concomitantly administered compared to either alone", 
                "measure": "hSBA GMT, percentage of subjects with hSBA \u22651:5 and percentage of subjects with hSBA \u2265 1:8 against serogroups B (all indicator strains), A, C, W-135 and Y", 
                "safety_issue": "No", 
                "time_frame": "30 days after 3th vaccination, pre-4th vaccination and 30 days after 4th vaccination"
            }, 
            {
                "measure": "Within subject Geometric Mean Ratios (GMRs) and percentage of subject with four-fold increase in hSBA titers, at one months after fourth vaccination versus pre-fourth vaccination", 
                "safety_issue": "No", 
                "time_frame": "30 days after 4th vaccination"
            }, 
            {
                "measure": "Percentage of subjects with solicited AE, unsolicited AE, medically attended AEs, AEs leading to withdrawn and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of study, within an expected average of 11 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}